BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Bayer AG (BAY.F), Johnson & Johnson (JNJ)’s Xarelto Prevented Repeat Strokes in Analysis


5/25/2011 7:26:46 AM

Bayer AG (BAYN) and Johnson & Johnson (JNJ)’s blood-thinner Xarelto was effective in preventing repeat strokes in an analysis of high-risk patients from the Rocket-AF trial, Bayer said today in a study presented at the European Stroke Conference in Hamburg, Germany.

Patients who took Xarelto, known chemically as rivaroxaban, showed a 13 percent lower risk of having another stroke than patients who took the previous standard therapy warfarin, with a similar risk of bleeding as a side effect and lower rates of fatal bleeding, the Leverkusen, Germany-based company said in a statement.


Read at Bloomberg
Read at Market Watch


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->